NCT02221479View on ClinicalTrials.gov

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Multiple Myeloma

Interventions

DRUG

plerixafor GZ316455

Pharmaceutical form:vial Route of administration: subcutaneous injection

DRUG

Filgrastim

Pharmaceutical form:vial Route of administration: subcutaneous injection

Trial Locations (5)

Unknown

Investigational Site Number 392105, Kamogawa-Shi

Investigational Site Number 392103, Kyoto

Investigational Site Number 392102, Nagoya

Investigational Site Number 392104, Okayama

Investigational Site Number 392101, Shibuya-Ku

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02221479 - Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | Biotech Hunter | Biotech Hunter